Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 801–900 of 1,002
Mechanisms of HIF-driven immunosuppression in tumour microenvironment
Bandopadhyay, S., & Patranabis, S. (2023) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-023-00186-z · Cited by 25
What happens to regulatory T cells in multiple myeloma
Chen, H., Wang, X., Wang, Y., & Chang, X. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01765-8 · Cited by 23
Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions
Liu, J., Zhang, H., Jia, L., & Sun, H. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2893 · Cited by 19
“Our results suggest that Treg cells and hypoxia may induce the immune escape and ovarian cancer cell metastasis, as previously proposed in other studies (33,34).”
Marcu, L. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.05.002 · Cited by 23
Ao, C., & Zeng, K. (2018) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2018.08.014 · Cited by 21
Elemam, N. M., Al‐Jaderi, Z., Hachim, M. Y., & Maghazachi, A. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02319-7 · Cited by 23
de Miranda, F. S., Guimarães, J. P. T., Menikdiwela, K. R., Mabry, B., Dhakal, R., Rahman, R. L., Moussa, H. M., & Moustaïd‐Moussa, N. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111245 · Cited by 24
Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 24
“, 2015) and regulatory T cells are recruited through angiogenic and hypoxia-induced signaling (Facciabene et al., 2011; Voron et al., 2015; Wallin et al., 2016; Palazon et al., 2017).”
BackgroundCbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells
Sun, M. T., Ha, N., Pham, D.-H., Frederick, M. A., Sharma, B., Naruse, C., Asano, M., Pipkin, M. E., George, R. E., & Thai, T. (2017) · Scientific Reports · doi:10.1038/srep42888 · Cited by 20
Jiang, K., Liu, H., Chen, X., Wang, Z., Wang, X., Gu, X., Tong, Y., Ba, X., Yu, H., Wu, J., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s513207 · Cited by 19
Spatial heterogeneity in glioblastoma: Decoding the role of perfusion
Saha, S., Bhat, A., Kukal, S., Phalak, M., & Kumar, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189383 · Cited by 19
Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy
Liu, L., Wu, D., Qian, Z., Ying, J., You, Y., Wang, Y., Zhang, F., Ning, X., Mei, J., Iqbal, J., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02682-8 · Cited by 23
“Hypoxia-induced factors, such as CCL28 and VEGF, not only stimulate angiogenesis but also in fl uence T-cell traf fi cking [79].”
Antitumor Therapy Targeting the Tumor Microenvironment
Gao, Y., Pan, Z., Li, H., & Wang, F. (2023) · Journal of Oncology · doi:10.1155/2023/6886135 · Cited by 22
Massenet-Regad, L., Poirot, J., Jackson, M., Hoffmann, C., Amblard, E., Onodi, F., Bouhidel, F. A., Djouadou, M., Ouzaïd, I., Xylinas, E. N., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108367 · Cited by 20
“Most of the identified interactions are involved in angiogenesis (such as CCL28/CCR10 , or VEGFA/FLT1 + KDR ) 24 or known to play a role in malignant and stromal cell proliferation (such as EDN1/EDNRB with endothelial cells, EDN1/EDNRA with fibroblasts, and all interactions targeting EGFR on cancer…”
BackgroundXing, Z., Li, X., He, Z. N. T., Fang, X., Liang, H., Kuang, C., Li, A., & Yang, Q. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070870 · Cited by 19
Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond
Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544532 · Cited by 24
Targeting the Tumor Microenvironment to Enhance Pediatric Brain Cancer Treatment
Batista, A., Riedemann, L., Vardam, T. D., & Jain, R. K. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000125 · Cited by 19
Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious?
Facciabene, A., Santoro, S. P., & Coukos, G. (2012) · OncoImmunology · doi:10.4161/onci.19401 · Cited by 18
“We recently further characterized the pathways that drive Tregs into ovarian cancer and demonstrated a key role for CCL28 in Treg recruitment, a chemokine that we found to be directly upregulated by hypoxia.(6) Tumor progression is critically linked not only to immune escape but also to the development of neovasculatu…”
BackgroundSelf-citationThe role of the chemokine receptor XCR1 in breast cancer cells
Yang, X. L., Qi, L. G., Lin, F. J., & Ou, Z. L. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s126184 · Cited by 19
“For example, tumor hypoxia promotes the recruitment of regulatory T (Treg) cells through the induction of expression of CCL28, which, in turn, promotes tumor tolerance and angiogenesis.(19) Chemokine receptor CXCR4 gene silencing can inhibit breast cancer metastasis to the lung in nude mice,(20) and posttranscriptiona…”
Hypoxic Regulation of Neutrophils in Cancer
Triner, D. A., & Shah, Y. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174189 · Cited by 23
Immunosurveillance of cancer cell stress
Lorenzo‐Herrero, S., Sordo‐Bahamonde, C., Gonzalez, S. R., & López‐Soto, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.198 · Cited by 19
“Further, tumor-associated hypoxia enhances Treg cell infiltration and accumulation via chemotactic factors, such as C-C motif chemokine ligand 28 (CCL28), promoting tumor tolerance and angiogenesis in ovarian cancer [90].”
Cell-mediated immune resistance in cancer
Wang, Y., Hays, E., Rama, M., & Bonavida, B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.98 · Cited by 25
“In practice, others have found that tumor hypoxia upregulates CCL28, a chemokine that recruits CD4+CD25+FOXP3+ Treg cells in an ovarian cancer mouse model, linking it to a more tolerigenic TME and increased tumor vascularization via vascular endothelial growth factor A([122]).”
BackgroundPneumatically Actuated Microfluidic Platform for Reconstituting 3D Vascular Tissue Compression
Ahn, J., Lee, H., Kang, H., Choi, H., Son, K., Yu, J., Lee, J., Lim, J., Park, D., Cho, M., et al. (2020) · Applied Sciences · doi:10.3390/app10062027 · Cited by 19
“Blood vessel compression can also exclude tumor sites from the systemic administration of therapeutic cancer drugs, reducing the accessibility of cancer drugs to the target cancerous cells [13,14].”
BackgroundSun, X., Zhou, Z., Zhang, Y., Wang, J., Zhao, X., Jin, L., Zhai, T., Liu, X., Zhang, J., Mei, W., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01954-4 · Cited by 18
Sun, C., Wang, B., Dong, B., Du, W., Zhou, G., Yan, H., Wei, H., Li, W., Chen, S., Wang, H., et al. (2021) · ECS Journal of Solid State Science and Technology · doi:10.1149/2162-8777/ac0f11 · Cited by 18
Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
Bronger, H. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1475-4335 · Cited by 20
“CCL28 is induced by hypoxia in preclinical ovarian cancer models, attracts CCR10-positive T regs and is associated with poor survival [62].”
Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis
Chen, X., Lan, H., He, D., Xu, R., Zhang, Y., Cheng, Y., Chen, H., Xiao, S., & Cao, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645839 · Cited by 24
Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell–Derived Thrombospondin-1
Schadler, K., Crosby, E. J., Zhou, A. Y., Bhang, D. H., Braunstein, L. Z., Baek, K. H., Crawford, D. A., Crawford, A., Angelosanto, J., Wherry, E. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0094 · Cited by 18
Kim, H., Lee, G., Sohn, S.-H., Lee, C., Kwak, J. W., & Bae, H. (2016) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2016.20.3.261 · Cited by 18
“demonstrated that Treg cell recruitment has a key role in establishing the vascular endothelial growth factor A (VEGFA)-rich tumor microenvironment and increasing tumor angiogenesis, whereas the depletion of Treg cells reduces tumor VEGFA levels and tumor vascularization [31].”
BackgroundSinno, S., Imperatore, J. A., Bai, S., Gomes-Jourdan, N., Mafarachisi, N., Coronnello, C., Zhang, L., Jašarević, E., Osmanbeyoglu, H. U., Buckanovich, R. J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175147 · Cited by 18
“The ascites TME in the i.p. model is highly hypoxic with increased concentration of immunosuppressive chemokines and high numbers of regulatory T cells and immunosuppresive myeloid cells, making it particularly resistant to immunotherapy (36, 76–78).”
Self-citationThe role and mechanism of compressive stress in tumor
Tan, M., Song, B., Zhao, X., & Du, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1459313 · Cited by 23
“Blood vessel compression and solid stress protect cancer cells from the host immune system, and even when immune cells successfully reach tumor tissue (88), lack of oxygen impairs their killing potential (89).”
BackgroundChen, F., Fu, Y., Bai, G., Qiu, J., & Hua, K. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1634413 · Cited by 33
Chemokines: humble yet mighty players in the tumour microenvironment
Xavier, H., Moly, A. G. G., Thomas, J. A., Suboj, P., Suresh, A., Biju, E., Baby, A., Dominic, R. T., & Babykutty, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601756 · Cited by 19
“Another chemokine, CCL28 (mucosae associated epithelial chemokine) is also upregulated by hypoxia and HIF-1 a in human ovarian cancer cell lines (99).”
Thomas, J. A., Moly, A. G. G., Xavier, H., Suboj, P., Ladha, A., Gupta, G., Singh, S. K., Palit, P., & Babykutty, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1063051 · Cited by 21
“This tumor hypoxia specifically promotes the immunosuppressive function of T regulatory cells including its migration and activation at the tumor site (117).”
BackgroundDeciphering the tumour immune microenvironment cell by cell
Nabhan, M., Egan, D., Kreileder, M., Zhernovkov, V., Timosenko, E., Slidel, T. W. F., Dovedi, S. J., Glennon, K., Brennan, D. J., & Kölch, W. (2023) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2023.100383 · Cited by 20
Liao, Z., Li, M., Wen, G., Wang, K., Yao, D., Chen, E., Liang, Y., Xing, T., Su, K., Liang, C., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00415-7 · Cited by 18
Nicolini, A., Ferrari, P., Silvestri, R., & Gemignani, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.004 · Cited by 25
“Interestingly, the hypoxia-associated phenotype 9 cells showed CD274 gain (encoding PD-L1) and B2M ( 𝛽 2 microglobulin) heterozygous losses, suggesting a relationship of hypoxia with immune evasion.”
BackgroundSafaei, S., Alipour, S., Mahdavi, S. Z. B., Shalmashi, H., Khaze, V., Shanehbandi, D., Baradaran, B., & Kazemi, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10007-8 · Cited by 17
L’hypoxie tumorale: Un déterminant clé de la réactivité stromale et de la réponse antitumorale
Hasmim, M., Messai, Y., Noman, M. Z., & Chouaïb, S. (2014) · médecine/sciences · doi:10.1051/medsci/20143004017 · Cited by 21
“Ces résultats contradictoires illustrent la controverse actuelle qui entoure le rôle de HIF-1 dans la régulation des fonctions des cellules T. HIF-1 infuence également la différenciation des lymphocytes T. En effet, cette molécule induit l’expression de Foxp3 dans les cellules T CD4+, aboutissant à une ( ) Voir la Syn…”
BackgroundInfluentialGong, D.-H., Fan, L., Chen, H., Ding, K., & Yu, K. (2016) · Oncotarget · doi:10.18632/oncotarget.8680 · Cited by 20
“Moreover, CCR3 and CCR10 are the known receptors for CCL28 [6], which could promote tumor tolerance and angiogenesis [7].”
BackgroundPan, F., Li, W., Yang, W., Yang, X., Liu, S., Li, X., Zhao, X., Ding, H., Li, Q., & Pan, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.8996 · Cited by 18
“These data demonstrate that AGR2, regulated by HIF-1 α , could be a supervisory biomarker to detect vessel normalization induced by AuNPs.”
InfluentialKhatibi, A. S., Roodbari, N. H., Majidzade-A, K., Yaghmaei, P., & Farahmand, L. (2019) · Immunotherapy · doi:10.2217/imt-2019-0068 · Cited by 18
Maggs, L., & Ferrone, S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0358 · Cited by 20
Zhong, W., Wang, B., Yu, H., Lin, J., Xia, K., Hou, W., Yang, M., Chen, J., Yang, M., Wang, X., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1776060 · Cited by 19
Zhang, L., Fan, Y., Wang, X., Yang, M. Y., Wu, X., Huang, W., Lan, J., Liao, L., Huang, W., Lü, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554331 · Cited by 17
“We used X-tile analysis (38, 39) to divide patients in the GSE14520 dataset into two groups: those with high or low expression of CHST4 (Supplementary Figure S5).”
MethodSelf-citationMoody, A. S., Dayton, P. A., & Zamboni, W. C. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.94 · Cited by 26
“Tumor hypoxia and pH Another use of FCTNAs involves contrast that is designed to diagnose, determine different levels of, and treat tumor hypoxia, offering improved prognosis and decreased treatment resistance([198-201]).”
Backgroundβ3-Adrenoreceptors as ROS Balancer in Hematopoietic Stem Cell Transplantation
Pasha, A., Calvani, M., & Favre, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062835 · Cited by 18
Li, J., Cao, P., Chen, Y., Wang, J., Sun, X., Chen, R., Wang, G., & Hou, J. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113197 · Cited by 21
Gao, R.-L., Song, J., Sun, L., Wu, Z.-X., Yi, X.-F., Zhang, S., Huang, L., Ma, J., & Han, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920165 · Cited by 18
“The poor response might be due to tissue-specific immunoregulation and might be reversed by the addition of bevacizumab (Sandler et al., 2006; Facciabene et al., 2011; Tumeh et al., 2017; Pao et al., 2018).”
BackgroundWei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Hypoxia and the Tumor Secretome
Liu, Y., Ciotti, G. E., & Eisinger‐Mathason, T. S. K. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_4 · Cited by 18
Targeting Cbx3/HP1γ Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence
Le, P. T., Ha, N., Tran, N. K., Newman, A. G., Esselen, K. M., Dalrymple, J. L., Schmelz, E. M., Bhandoola, A., Xue, H., Singh, P. B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738958 · Cited by 18
Zhong, Y., Li, F., Zhang, S., Yang, Z., Ren, X., Cao, X., Xu, Y., Guo, D., Zhou, Y., Mao, F., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02917-7 · Cited by 18
Pan, Y., Yu, L., Liu, L., Zhang, J., Liang, S., Parshad, B., Lai, J., Ma, L., Wang, Z., & Rao, L. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.04.008 · Cited by 30
“Tumor hypoxia is often associated with immune evasion, which limits the effects of immunotherapy against CSCs [21,22].”
BackgroundLi, X., Li, D., Huang, X., Zhou, P., Shi, Q., Zhang, B., & Ju, X. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.02.007 · Cited by 19
García, V., Bonhoeffer, S., & Fu, F. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110185 · Cited by 17
Resolving the HIF paradox in pancreatic cancer
Fuentes, N. R., Phan, J. L., Huang, Y., Lin, D., & Taniguchi, C. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.033 · Cited by 17
Yan, J., Yuan, P., Gui, L., Wang, Z., Yin, P., Gao, W., & Ma, B. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211068958 · Cited by 17
Tregs are involved in VEGFA/ VASH1-related angiogenesis pathway in ovarian cancer
Qiao, S., Hou, Y., Rong, Q., Han, B., & Liu, P. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101665 · Cited by 17
Class 3 Semaphorin in Angiogenesis and Lymphangiogenesis
Bussolino, F., Giraudo, E., & Serini, G. (2013) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000353315 · Cited by 17
The current status of immunobased therapies for metastatic renal-cell carcinoma
Sathianathen, N. J., Krishna, S. R., Anderson, J. K., Weight, C., Gupta, S., Konety, B. R., & Griffith, T. S. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s134850 · Cited by 18
“For example, the production of CCL28 recruits regulatory T (T reg ) cells, which promote tumor tolerance and angiogenesis.(38) Furthermore, Munn et al have outlined the potent immunosuppressive qualities of the IDO enzyme within the tumor microenvironment.”
Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse
González, P. A., Carreño, L. J., Céspedes, P. F., Bueno, S. M., Riedel, C. A., & Kalergis, A. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/450291 · Cited by 17
“This molecule is expressed by tumors under hypoxic conditions and was shown to be able to recruit regulatory T cells to the tumor site that promotes tolerance at the tumor environment [176].”
BackgroundImpact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages
Flerin, N. C., Pinioti, S., Menga, A., Castegna, A., & Mazzone, M. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037044 · Cited by 17
Zhou, P., Zhang, W., Liao, Y., Zhai, Z., Lu, S., Jiang, S., Hu, W., & Gong, W. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002573 · Cited by 18
Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer
Li, J., Huang, H., Xie, R., Yang, R., Wang, H., & Wan, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631226 · Cited by 25
Negrete-García, M. C., Ramírez-Rodriguez, S. L., Rangel‐Escareño, C., Muñoz-Montero, S. A., Kelly-García, J., Vázquez-Manríquez, M. E., Santillán, P., Montaño, M., Ramírez-Martínez, G., Ramírez‐Venegas, A., et al. (2018) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.246.107 · Cited by 15
“Tumor microenvironment heterogeneity (Facciabene et al. 2011; Halama et al. 2011; Quail and Joyce 2013) might explain the lack of commonly altered miRNAs between that study and ours.”
Schroeter, C. B., Huntemann, N., Böck, S., Nelke, C., Kremer, D., Pfeffer, K., Meuth, S. G., & Ruck, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747143 · Cited by 16
New insights into T-cell exhaustion in liver cancer: from mechanism to therapy
Hao, L., Li, S., & Hu, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05083-5 · Cited by 17
Zou, Z., Luo, T., Wang, X., Wang, B., & Li, Q. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31278 · Cited by 16
“Under hypoxic conditions, Treg cells serve as an important source of VEGF expression, release TGF ‐ β , and indirectly regulate the expansion of CSCs by mediating angiogenesis (Facciabene et al., 2011).”
Chen, Y., Zhang, Z., Pan, F., Li, P., Yao, W., Chen, Y., Xiong, L., Wang, T., Li, Y., & Huang, G. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03135-3 · Cited by 17
“Notably, hypoxia induces the expression of CCL28 in ovarian cancer, which, in turn, enhances angiogenesis by recruiting regulatory T cells (Tregs) [17].”
BackgroundInfluentialTreg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects
Zhang, H., Felthaus, O., Eigenberger, A., Klein, S., & Prantl, L. (2024) · Cells · doi:10.3390/cells13181526 · Cited by 20
An on‐Demand Oxygen Nano‐vehicle Sensitizing Protein and Nucleic Acid Drug Augment Immunotherapy
Zhang, S., Wang, X., Chen, X., Shu, D., Lin, Q., Zou, H., Dong, J., Wang, B., Tang, Q., Li, H., et al. (2025) · Advanced Materials · doi:10.1002/adma.202409378 · Cited by 19
Pan, G.-Q., Yan, Y., Li, R., Chen, X., Zhang, S.-P., Qu, Y., Dong, R., Zhou, Y. J., Zhang, T.-S., Chen, Z.-Q., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156304 · Cited by 19
Hydrogel Nanosensors for Biophotonic Imaging of Chemical Analytes
Ray, A., & Kopelman, R. (2013) · Nanomedicine · doi:10.2217/nnm.13.166 · Cited by 17
“lack of oxygen concentration in the tumor core and has been shown to promote tumor aggressiveness, local recurrence, metastasis [21, 22] as well as resistance to different therapies, such as Radiation, Chemo and Photodynamic therapy [23].”
BackgroundComplicated prognostic values of CCL28 in breast cancer by subtype
Gong, D.-H., Chen, Y., Ma, D., Chen, H., Ding, K., & Yu, K. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.02.26 · Cited by 15
Aziz, N. S., Yusop, N., & Ahmad, A. (2020) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x15666200127145923 · Cited by 17
Circulating Tregs Accumulate in Omental Tumors and Acquire Adipose-Resident Features
Liu, M., Starenki, D., Scharer, C. D., Silva-Sánchez, A., Molina, P. A., Pollock, J. S., Cooper, S. J., Arend, R. C., Rosenberg, A. F., Randall, T. D., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0880 · Cited by 16
Li, L., Zhen, M., Wang, H., Sun, Z., Cao, X., Li, J., Liu, S., Zhao, Z., Zhou, C., Wang, C., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101702 · Cited by 15
Hypoxia in Head and Neck Cancer in Theory and Practice: A PET-Based Imaging Approach
Marcu, L. G., Harriss-Phillips, W. M., & Filip, S. M. (2014) · Computational and Mathematical Methods in Medicine · doi:10.1155/2014/624642 · Cited by 15
“Hypoxia was shown to promote angiogenesis and distant metastases [4, 5] processes that add to the challenge of managing hypoxic solid tumours.”
BackgroundShen, L., Qu, R., Shi, H., Huang, F., An, Y., & Shi, L. (2016) · Biomaterials Science · doi:10.1039/c6bm00046k · Cited by 15
Napoletano, C., Bellati, F., Ruscito, I., Pernice, M., Zizzari, I. G., Caponnetto, S., Tomao, F., Frigerio, L., Liberati, M., Rughetti, A., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11080 · Cited by 16
Engineering T cells for adoptive therapy: outsmarting the tumor
Kunert, A., & Debets, R. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.014 · Cited by 20
Shu, C., Sun, P., Xie, H., Huang, W., Qi, J., & Ma, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s237182 · Cited by 15
Aoki, T., Nishida, N., & Kudo, M. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211056853 · Cited by 15
D'Andrea, M. R., Cereda, V., Coppola, L., Giordano, G., Remo, A., & Santis, E. D. (2021) · Cancers · doi:10.3390/cancers13235917 · Cited by 18
“Furthermore, Tregs indirectly facilitate tumor angiogenesis by inhibiting Th1 cell activation and polarizing TAMs into the M2-like phenotype [81,82].”
BackgroundRadiation therapy and antiangiogenic therapy: Opportunities and challenges
Bendavid, J., & Modesto, A. (2022) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2022.06.012 · Cited by 16
Torres-Mejia, E., Weng, S., Whittaker, C. A., Nguyen, K. B., Duong, E., Yim, L., & Spranger, S. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0184 · Cited by 17
Iyengar, S., Zhan, C., Lu, J., Korngold, R., & Schwartz, D. H. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.04.029 · Cited by 17
LIU, G.-X., Lan, J. Q., Sun, Y., Hu, Y., & Jiang, G. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.544 · Cited by 14
“Contradictorily, research (15) has revealed that CCL28 plays a role in immune escape due to its recruitment of Treg.”
Non-Invasive Imaging of Normalized Solid Stress in Cancers in Vivo
Islam, M. T., Tasciotti, E., & Righetti, R. (2019) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2019.2932059 · Cited by 17
“Hypoxia is responsible for impaired perfusion and can reduce the killing potential of the immune cells [9].”
BackgroundMonocytes mediate Salmonella Typhimurium ‐induced tumor growth inhibition in a mouse melanoma model
Johnson, S. A., Ormsby, M. J., Wessel, H. M., Hulme, H., Bravo‐Blas, A., McIntosh, A., Mason, S. M., Coffelt, S. B., Tait, S. W. G., Mowat, A. M., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202048913 · Cited by 16
Chung, K. P. S., Leung, R. W. H., & Lee, T. K. (2021) · Cancers · doi:10.3390/cancers13133191 · Cited by 16
Sun, X., Zhang, J., Xiu, J., Zhao, X., Yang, C., Li, D., Li, K., Hu, H., Qiao, M., Chen, D., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm00455k · Cited by 17
Papapavlou, G., Hellberg, S., Huang, J., Khademi, M., Kockum, I. S., Carlsson, H., Tjernberg, I., Svenvik, M., Lind, J., Blomberg, M. I., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.930947 · Cited by 22
“CCL28 has been linked to the recruitment of Treg cells (46, 47), however CCL28 and its receptor CCR10 were also proposed to be pathogenic in rheumatoid arthritis (47).”
BackgroundConducive target range of breast cancer: Hypoxic tumor microenvironment
Cheng, W., Xiao, X., Liao, Y., Cao, Q., Wang, C., Li, X., & Jia, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.978276 · Cited by 16
Croci, D. O., Méndez‐Huergo, S. P., Cerliani, J. P., & Rabinovich, G. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_29 · Cited by 16
Chemokine CCL28 Is a Potent Therapeutic Agent for Oropharyngeal Candidiasis
He, J., Thomas, M. A., de Anda, J., Lee, M. W., Why, E. V., Simpson, P. M., Wong, G. C. L., Grayson, M. H., Volkman, B. F., & Huppler, A. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00210-20 · Cited by 15
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 16
GPCRs in head and neck squamous cell carcinoma
Wu, V. H., & Gutkind, J. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00015-9 · Cited by 13
Yang, Z., Zheng, Y., Wu, H., Xie, H., Zhao, J., Chen, Z., Li, L., Yue, X., Zhao, B., & Bian, E. (2023) · Human Genomics · doi:10.1186/s40246-023-00480-w · Cited by 14
“In addition, tumors secrete the chemokine CCL28, selectively attracting Tregs and increasing their functions, which can inhibit effector T cells and DCs from exerting immunosuppressive effects [71].”
Background
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.